Pomegranate extract specifically inhibits Clostridium difficile growth and toxin production without disturbing the beneficial bacteria in vitro
Authors Sukumar MR, König B
Received 23 January 2018
Accepted for publication 12 May 2018
Published 16 November 2018 Volume 2018:11 Pages 2357—2362
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Varun Dwivedi
Peer reviewer comments 2
Editor who approved publication: Dr Joachim Wink
Murugapillai Rathinam Sukumar, Brigitte König
Institute for Medical Microbiology and Epidemiology of Infectious Diseases, Leipzig University Hospital, Leipzig, Germany
Objective: The aim of this study was to assess the pomegranate juice against the growth and toxin production of multidrug-resistant Clostridium difficile hypervirulent strain NAP1/027/BI and also against the growth of beneficial bacteria to prevent or suppress C. difficile infection (CDI).
Materials and methods: Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were taken as parameters for the assessment of antimicrobial property of the pomegranate juice. Four different C. difficile hypervirulent strains NAP1/027/BI, Lactococcus lactis spp., Lactobacillus casei, and Bifidobacterium animalis were subjected to the broth dilution method to determine the MIC and MBC. Enzyme-linked immunosorbent assay (ELISA) was performed to determine clostridial toxin B (TcdB) production in the presence of pomegranate juice.
Results: The MIC and MBC of pomegranate juice containing punicalagin were found to be 390 µg/mL for all C. difficile hypervirulent strain NAP1/027/BI, and the growth of L. lactis spp., L. casei, and B. animalis was not inhibited. Pomegranate juice reduced TcdB production in C. difficile hypervirulent strain NAP1/027/BI.
Conclusion: This study highlights the potential of pomegranate juice to reduce CDI without affecting the beneficial bacteria. Pomegranate juice may be a useful antimicrobial agent to prevent or suppress CDI, avoiding the use of antibiotics.
Keywords: Clostridium difficile, pomegranate juice, antimicrobial agent, CDI
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]